Harvard Bioscience (HBIO) Tops Q4 EPS by 1c

Harvard Bioscience (NASDAQ: HBIO) reported Q4 EPS of $0.06, $0.01 better than the analyst estimate of $0.05. Revenue for the quarter came in at $24.6 million versus the consensus estimate of $24.15 million.

GUIDANCE:

Harvard Bioscience sees Q1 2025 revenue of $19-21 million.

For earnings history and earnings-related data on Harvard Bioscience (HBIO) click here.

You May Also Be Interested In

• Ericsson (ERIC) Tops Q2 EPS by 3c
• Jefferies Starts Busy Ming Group (1768:HK) at Buy
• Piper Sandler Upgrades Halliburton (HAL) to Overweight